Prevotella bivia

check icon Optimal Result: 0 - 2000 Copies/ul eq..

Prevotella bivia (P. bivia) is an anaerobic, non-pigmented, gramnegative bacillus which is naturally present in the human female vaginal tract, and it is also occasionally seen in the oral cavity. It has a high proliferative potential in the presence of estrogen. Therefore, its involvement in, vaginal tract infections such as endometritis and pelvic inflammatory disease, has been well described in the literature. If left untreated, it may cause more serious conditions, such as cuff abscess, abdominal wall empyema, or septic arthritis.

The DNA of P. bivia has been detected from human vaginal epithelia in 40% of healthy women. The prevalence is relatively higher in women with bacterial vaginosis (BV). Its detection from the glans penis indicates that it is a causative factor of BV in female sex partners. It is also probable, however, that traumatic events such as human bite might cause P. bivia infections leading to suppurative inguinal adenitis during orogenital sex. It is also a normal oral and vaginal flora as well as a predominant type of bacillus isolated from the respiratory tract infections and their complications, including aspiration pneumonia, lung abscess, chronic otitis media, chronic sinusitis, abscesses in the oral cavity, human bites, brain abscesses, and osteomyelitis. Moreover, P. bivia is the important pathogen in obstetric and gynecologic infections.

There is a report suggesting that the concentrations of P. bivia and lipopolysaccharide in the vaginal fluid may contribute to the severity of BV and to the development of adverse pregnancy outcomes, such as preterm labor, premature rupture of membranes, postpartum endometritis, and postoperative pelvic infection.

References:

1. Riesbeck K. Paronychia due to Prevotella bivia that resulted in amputation: fast and correct bacteriological diagnosis is crucial. J Clin Microbiol 2003;41: 4901-3. [L]

2. Hsu GJ, Chen CR, Lai MC, Luh SP. Chest wall abscess due to Prevotella bivia. J Zhejiang Univ Sci B 2009;10: 233-6. [L]

3. Laiho K, Kotilainen P. Septic arthritis due to Prevotella bivia after intra-articular hip joint injection. Joint Bone Spine 2001;68: 443-4. [L]

4. Purushothaman B, Lakshmanan P, Gatehouse S, Fender D. Spondylodiscitis due to Prevotella associated with ovarian mass: a rare case report and review of literature. World Neurosurg 2010;73: 119-22. [L]

5. Salman SA, Baharoon SA. Septic arthritis of the knee joint secondary to Prevotella bivia. Saudi Med J 2009;30: 426-8.

6. Mirza A, Bove JJ, Litwa J, Appelbe G. Mixed Infections of the Paronychium with Prevotella bivia. J Hand Microsurg 2012;4: 77-80.

7. Srinivasan S, Fredricks DN. The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis 2008;2008: 750479. [L]

8. Price LB, Liu CM, Johnson KE, Aziz M, Lau MK, Bowers J, et al. The effects of circumcision on the penis microbiome. PLoS One 2010;5: e8422. [L]

9. Aroutcheva A, Ling Z, Faro S. Prevotella bivia as a source of lipopolysaccharide in the vagina. Anaerobe 2008;14: 256-60. [L]

10. Smayevsky J, Canigia LF, Lanza A, Bianchini H. Vaginal microflora associated with bacterial vaginosis in nonpregnant women: reliability of sialidase detection. Infect Dis Obstet Gynecol 2001;9: 17-22. [L]

11. Managing recurrent bacterial vaginosis, J Wilson [L]

What does it mean if your Prevotella bivia result is too high?

Prescribable antibiotics are included as prescribing options due to lack of detected antibiotic resistance genes. Physicians should use this as a guide and prescribe antibiotics based upon patient symptoms and medical history, including such factors as allergies, other medications, and pregnancy status: Metronidazole, Secnidazole, Tinidazole

What therapeutic options do we have to manage or try to prevent further recurrences of BV?

Bacteriotherapy

Bacteriotherapy, using harmless bacteria to displace pathogenic organisms is considered ‘‘natural’’ and without any side effects, but there is lack of efficacy data with few randomised controlled trials (RCT). The lactobacilli (LB) used need to be able to adhere to vaginal epithelial cells, and to produce hydrogen peroxide. If given orally the LB need to pass through the intestinal tract and ascend from the perianal area into the vagina. There have been several publications of attempts to restore vaginal flora by recolonising with LB using both intravaginal and oral administration. However, the LB used have not been vaginal strains. LB strains from yoghurt adhere less well to vaginal cells than clinical isolates. In a double blind RCT looking at LB as a treatment for BV, vaginal pessaries containing L acidophilus were used for 6 days. With active therapy 57% of women cleared their infection compared with 0% of those given placebo, but only three remained BV free after menstruation.

It was thought there was a problem with LB adherence. One group of researchers has published case reports and small case series of vaginal and oral LB replacement. They report successful vaginal colonisation following administration by both routes. This group have recently published a RCT of oral capsules of L rhamnosus GR-1 and L fermentum RC-14 for 60 days. Microscopy showed restoration to normal flora from asymptomatic BV in 37% women receiving LB treatment compared with 13% receiving placebo. This significant improvement in vaginal flora was also accompanied by a significant increase in LB at day 60.

These results are encouraging but we do not know if the nonvaginal LB will remain in the vagina to protect against further episodes of BV. A RCT of oral Lactobacillus GG drink for the prevention of recurrent urinary tract infection (UTI) showed no reduction in UTIs over 12 months. The principles of UTI prevention by this method are similar to that of BV prevention—that is, LB replacement to protect against bacterial overgrowth, so it is unlikely that oral Lactobacillus GG would be beneficial for BV prevention. In a study looking at mechanisms of LB blockage of uropathogen adherence to vaginal epithelial cells, L crispatus showed greater capacity to block uropathogen adherence than other LB. A study looking at sustained vaginal colonisation of LB showed 40% of women remained colonised with L crispatus and L jensenii for over 8 months compared with 5% of women colonised with other LB spp indicating better ability to adhere to vaginal cells.

There is currently a RCT using vaginal pessaries containing L crispatis to attempt to recolonise the vagina with LB (S Hillier, personal communication). This is the first study of replacement with one of the main vaginal hydrogen peroxide producing LB.

Maintaining vaginal pH at 4.5

The main goal of therapy here is to keep the vaginal pH at 4.5 or less, in order to prevent overgrowth of pathogens until the normal LB are re-established and able to maintain the pH themselves. In a RCT of 42 women with recurrent BV using intravaginal lactate gel to try to prevent BV recurrences, 17 women used lactate gel for 3 days immediately after menstruation for 6 months, the remainder used placebo. The 6 months on-treatment analysis showed that 88% were clear of BV with active treatment compared with only 10% with placebo. Intent to treat analysis at 6 months showed 71% were clear with treatment and 4.8% were clear with placebo. The treatment was well tolerated but there was a large dropout rate, particularly in the placebo arm because of malodour. The authors suggested more intensive treatment might have improved this.

Preventing overgrowth of BV associated organisms

Although intermittent therapy, on an episodic or prophylactic basis, is frequently used for recurrent BV, there are very few publications on this. Hay et al advised women with recurrent BV to collected daily vaginal specimens for between 1– 12 months, to try to identify the times of recurrence. BV recurrences most often arose within the first 7 days of the menstrual cycle, and frequently followed candida infection.2 Consequently they advised oral or intravaginal metronidazole for 3 days at the onset of menstruation for 3– 6 months, and add antifungal treatment if there is a history of candidiasis.

Better treatments and/or combined treatments

Using oral or vaginal preparations of metronidazole and clindamycin, 80–90% of women will have an initial response to treatment but 15–30% will get a recurrence within 3 months.

In women with recurrent BV the initial response rate appears to be lower. The heterogeneity of microorganisms involved in BV may contribute to treatment failure and high recurrence rates. Clindamycin has better activity against M hominis, Mobiluncus spp, and G vaginalis than metronidazole, but metronidazole has the advantage of not affecting LB. In trials comparing treatments, cure rates for metronidazole 400 mg or 500 mg twice daily for 7 days have been equivalent to clindamycin vaginal cream daily for 3–7 days, and to metronidazole vaginal gel once or twice per day for 5 days. In the absence of better treatments would women with recurrent BV benefit from longer courses of current treatment? This question remains unanswered. In view of the association between lactobacilli, hydrogen peroxide production, vaginal pH, and overgrowth of BV associated bacteria, just trying to adjust one of these may help some women with recurrent BV, but it may not be enough to resolve all cases. Would a combined approach work better? There are very few publications on this, but they do suggest that the answer might be yes. A small study using single dose oral metronidazole followed by vaginal lactate tablets compared to no vaginal maintenance treatment reported an improved rate of normal vaginal flora of 94% compared to 71%.

Another small study compared tinidazole 2 g single oral dose followed by acidic vaginal gel for 3 weeks with 2% clindamycin vaginal cream 5 g per night for 7 nights. At 4 weeks the clinical cure rate was 94% versus 77%. The vaginal pH was ,4.5 in 78% and 38% respectively.

Conclusions

There is an important inter-relation between lactobacilli, hydrogen peroxide production, vaginal pH, and overgrowth of BV associated bacteria, but the initiating factor for BV remains a mystery. From current evidence it appears that a rise in vaginal pH allowing the overgrowth of bacteria may be more important than reduction of LB+. However long term colonisation with LB+ is necessary to help maintain an acidic pH and support the LB+/myeloperoxidase/chloride system. Therapies aimed at one aspect of this inter-relation may help some women with recurrent BV, but a combined approach might work better. Probably the ideal way of managing recurrent BV would be to tackle all aspects of the interrelation by replacing the lactobacilli, at the same time maintaining the vaginal pH at 4.5, and if necessary also adding in prophylactic treatment to control overgrowth of bacteria. If the current RCT of vaginal LB+ replacement proves successful this approach may soon be possible.

All Your Lab Results.
One Simple Dashboard.

Laboratories

Bring All Your Lab Results Together — In One Place

We accept reports from any lab, so you can easily collect and organize all your health information in one secure spot.

lab corp logo
genova diagnostics logo
quest diagnostics logo
dutch test logo
doctors data logo
vibrant america logo
diagnostic solutions logo
zrt laboratory logo
the great plains laboratory logo
cyrex laboratories logo
spectracell logo

Pricing Table

decoration

Personal plans

$15/ month

Complete Plan

Access your lab reports, explanations, and tracking tools.

  • Import lab results from any provider
  • Track all results with visual tools
  • Customize your reference ranges
  • Export your full lab history anytime
  • Share results securely with anyone
  • Begin with first report entered
  • Cancel or upgrade anytime

$250/ once

Unlimited Account

Pay once, access everything—no monthly fees, no limits.

  • Import lab results from any provider
  • Track all results with visual tools
  • Customize your reference ranges
  • Export your full lab history anytime
  • Share results securely with anyone
  • Receive 10 reports entered for you
  • Skip the $15/month subscription — no recurring payments ever

$45/ month

Pro Monthly

Designed for professionals managing their clients' lab reports

  • Import lab results from any provider
  • Track lab results for multiple clients
  • Customize reference ranges per client
  • Export lab histories and reports
  • Begin with first report entered by us
  • Cancel or upgrade anytime

About membership

What's included in a Healthmatters membership

microscope icon Import Lab Results from Any Source

person icon See Your Health Timeline

book icon Understand What Your Results Mean

textbook icon

textbook icon Visualize Your Results

folder icon

folder icon

card icon Securely Share With Anyone You Trust

Let Your Lab Results Tell the Full Story

What Healthmatters Members Are Saying

5 stars rating

I have been using Healthmatters.io since 2021. I travel all over the world and use different doctors and health facilities. This site has allowed me to consolidate all my various test results over 14 years in one place. And every doctor that I show this to has been impressed. Because with  any health professional I talk to, I can pull up historical results in seconds. It is invaluable. Even going back to the same doctor, they usually do not have the historical results from their facility in a graph format. That has been very helpful.

Anthony

Unlimited Plan Member since 2021

5 stars rating

What fantastic service and great, easy-to-follow layouts! I love your website; it makes it so helpful to see patterns in my health data. It's truly a pleasure to use. I only wish the NHS was as organized and quick as Healthmatters.io. You've set a new standard for health tracking!

Karin

Advanced Plan Member since 2020

5 stars rating

As a PRO member and medical practitioner, Healthmatters.io has been an invaluable tool for tracking my clients' data. The layout is intuitive, making it easy to monitor trends and spot patterns over time. The ability to customize reports and charts helps me present information clearly to my clients, improving communication and outcomes. It's streamlined my workflow, saving me time and providing insights at a glance. Highly recommended for any practitioner looking for a comprehensive and user-friendly solution to track patient labs!

Paul

Healthmatters Pro Member since 2024

Use promo code to save 10% off any plan.

Frequently asked questions

Healthmatters is a personal health dashboard that helps you organize and understand your lab results. It collects and displays your medical test data from any lab in one secure, easy-to-use platform.

  • Individuals who want to track and understand their health over time.
  • Health professionals, such as doctors, nutritionists, and wellness coaches, need to manage and interpret lab data for their clients.

With a Healthmatters account, you can:

  • Upload lab reports from any lab
  • View your data in interactive graphs, tables, and timelines
  • Track trends and monitor changes over time
  • Customize your reference ranges
  • Export and share your full lab history
  • Access your results anytime, from any device

Professionals can also analyze client data more efficiently and save time managing lab reports.

Healthmatters.io personal account provides in-depth research on 4000+ biomarkers, including information and suggestions for test panels such as, but not limited to:

  • The GI Effects® Comprehensive Stool Profile,
  • GI-MAP,
  • The NutrEval FMV®,
  • The ION Profile,
  • Amino Acids Profile,
  • Dried Urine Test for Comprehensive Hormones (DUTCH),
  • Organic Acids Test,
  • Organix Comprehensive Profile,
  • Toxic Metals,
  • Complete Blood Count (CBC),
  • Metabolic panel,
  • Thyroid panel,
  • Lipid Panel,
  • Urinalysis,
  • And many, many more.

You can combine all test reports inside your Healthmatters account and keep them in one place. It gives you an excellent overview of all your health data. Once you retest, you can add new results and compare them.

If you are still determining whether Healthmatters support your lab results, the rule is that if you can test it, you can upload it to Healthmatters.

shield icon

We implement proven measures to keep your data safe.

At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.

gdpr compliance image hipaa compliance image